Corvus Pharmaceuticals to Present at SITC’s 31st Annual Meeting

BURLINGAME, Calif., Nov. 02, 2016 -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced it will present preliminary clinical and biomarker data from its from its ongoing Phase 1/1b study of CPI-444 as a single agent, and in combination with Genentech’s TECENTRIQ® (atezolizumab), at the Society for Immunotherapy of Cancer’s (SITC) 31^st Annual Meeting & Associated Programs taking place November 9 – 13 in National Harbor, Maryland.

Following are the details of Corvus' two poster presentations:

• Phase 1/1b multicenter trial of CPI-444, an adenosine A2a receptor (A2aR) antagonist as a single agent and in combination with atezolizumab (atezo) in patients with advanced solid tumors (Poster #149)

Authors: John Powderly II¹ (presenter), Joshua Brody², John Nemunaitis³, Leisha Emens⁴, Jason J. Luke⁵, Amita Patnaik⁶, Ian McCaffery⁷, Richard Miller⁷, Ginna Laport⁷
Affiliations: ¹Carolina BioOncology Institute, Huntersville, NC; ²Mount Sinai School of Medicine, New York, NY; ³Mary Crowley Cancer Research Center, Gradalis, Inc., Medical City Dallas Hospital, Baylor University Medical Center, Dallas, TX; ⁴Johns Hopkins School of Medicine, Baltimore, MD; ⁵University of Chicago School of Medicine; ⁶ South Texas Accelerated Research Therapeutics, San Antonio, TX, ⁷Corvus Pharmaceuticals, Burlingame, CA

Session Date and Time: Friday, November 11, 12:15 – 1:30 p.m. and 6:15 – 7:30 p.m. ET

Location: Gaylord National Hotel & Convention Center, Prince George’s Exhibition Hall AB

• CPI-444: a potent and selective inhibitor of adenosine 2A receptor (A2AR) induces anti-tumor responses alone and in combination with anti-PD-L1 (Poster #218)

Authors: Andrew Hotson¹ (presenter), Stephen Willingham¹, Po Y. Ho¹, Carmen Choy¹, Ginna Laport¹, Ian McCaffery¹, Richard Miller¹
Affiliations: ¹Corvus Pharmaceuticals, Burlingame, CA
Session Date and Time: Saturday, November 12, 11:45 a.m. – 1:00 p.m. and 6:45 – 8:00 p.m. ET
Location: Gaylord National Hotel & Convention Center, Prince George’s Exhibition Hall AB

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T-cells. Corvus’ lead product, CPI-444, is a checkpoint inhibitor that is designed to disable a tumor’s ability to subvert attack by the immune system by inhibiting adenosine in the tumor microenvironment. CPI-444 is a small molecule that is taken orally. CPI-444 is currently being evaluated in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and in combination with Genentech’s TECENTRIQ (atezolizumab), an anti-PD-L1 antibody. Corvus is conducting the trial with Genentech, a member of the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. For more information, visit: www.corvuspharma.com.

Investor Contact:
Jason Coloma, Ph.D.
SVP and Chief Business Officer
650-900-4511
[email protected]

Media Contact:
Julie Normart, W2O Group
415-946-1087
[email protected]